Volitionrx Ltd (VNRX) Stock Price, Quote & News

Company Profile

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes; Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progre...

Industry: Medical Devices

Sector: Healthcare

Phone: 646 650 1351

Website: volition.com

Address:

1489 West Warm Springs Road, Suite 110, Henderson, United States

jetty323 Feb. 21 at 3:04 AM

$VNRX 6.4 million shares diluted over the last month for payment in the convertible loan. The "hits just keep on comin." Stephen King would have a hard time imagining a more nightmarish storyline than what Reynolds has been allowed to create. His inept, naive, misguided management has been allowed to foster by the equally worthless BoD, who've done nothing to stop this ensuing trainwreck. They've dug themselves, and all their investors, into a hole so deep that it will be a near miracle for this to ever succeed. What a sham(e)

1 · Reply

moemog Feb. 20 at 12:50 AM

$VNRX 🚀💣 🔥🌡️⚡☄️🚨🚒🛫✈️

1 · Reply

jetty323 Feb. 20 at 12:35 AM

$VNRX This is great news! I'm sure there will quickly be a follow up into the market with this. Crickets for six weeks now, beautiful execution!! Now that's the leadership this company needs

1 · Reply

jetty323 Feb. 19 at 4:38 AM

$VNRX the single biggest thing Reynolds could do for the sake of shareholders would be to announce his departure as CEO and naming his replacement with a real Biotech executive. Currently the street completely discounts all his gibberish as he's proven time and again that he does not follow through. I would be (very) surprised if any big announcements come before 3/31 RS determination mtg; there are shenanigans going on and I'm betting that they are banking away much of the positive developments until this nightmare is behind them.

1 · Reply

SerendipiTea Feb. 19 at 1:39 AM

$VNRX Hey Cameron Reynolds, any day now would be a great day to announce something big and exciting. I keep adding more shares every day, but even I am growing weary here, mate. How about you join me, a half a million shares in the open market would be reassuring, tell us you've received that$5M milestone payment, announce another big strategic partnership. At this point, just about anything would suffice.

1 · Reply

ReturnStacking Feb. 17 at 12:54 PM

$VNRX Pre-revenue biotech; early-stage.

1 · Reply

moemog Feb. 17 at 12:20 PM

$VNRX ☕

0 · Reply

Kululu Feb. 13 at 9:08 PM

$VNRX this crap don’t even act like a Penny stock. Penny stocks sometimes go for 200-400 % run for no reason. It’s just bs stock

0 · Reply

2021er Feb. 12 at 7:13 PM

$VNRX

1 · Reply

jetty323 Feb. 12 at 6:48 AM

$VNRX the good news is that this is only the 76th month this has been in a downtrend; and even better you can ultimately only lose about 20 cent/share from here on out. The bad news...just re-read the good news.

0 · Reply

Volition Announces the Appointment of New Distributor for Nu.Q® Discover

Feb 9, 2026, 5:20 PM EST - 13 days ago

VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

Feb 4, 2026, 8:45 AM EST - 18 days ago

Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation

Jan 30, 2026, 8:50 AM EST - 23 days ago

VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays

Jan 27, 2026, 8:00 AM EST - 26 days ago

Volition Announces Data to Support Use of Nu.Q® NETs in New Indication

Jan 20, 2026, 8:25 AM EST - 4 weeks ago

Volition Continues to Extend Access to Nu.Q® Vet Cancer Test

Jan 16, 2026, 8:45 AM EST - 5 weeks ago

Volition Sponsors Symposium at Veterinary Meeting and Expo

Jan 8, 2026, 9:15 AM EST - 6 weeks ago

VolitionRx Secures $2.0 Million in Funding

Jan 8, 2026, 8:45 AM EST - 6 weeks ago

VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats

Dec 17, 2025, 8:45 AM EST - 2 months ago

Volition Issues Business Review 2025

Dec 11, 2025, 9:00 AM EST - 2 months ago

Volition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) Enrichment

Dec 8, 2025, 9:00 AM EST - 2 months ago

Volition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer

Dec 4, 2025, 9:00 AM EST - 2 months ago

VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis

Nov 25, 2025, 8:45 AM EST - 3 months ago

VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use

Nov 14, 2025, 12:51 PM EST - 3 months ago

VolitionRx Limited (VNRX) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 4:10 PM EST - 3 months ago

VolitionRx Limited Announces Third Quarter 2025 Financial Results and Business Update

Nov 10, 2025, 8:45 AM EST - 3 months ago

VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update

Oct 17, 2025, 8:00 AM EDT - 4 months ago

Volition Donates Nu.Q® Vet Cancer Tests to HOPE Animal-Assisted Crisis Response Dogs

Oct 10, 2025, 8:30 AM EDT - 4 months ago

VolitionRx Limited Announces Pricing of $6.0 Million Underwritten Public Offering of Common Stock and Common Stock Warrants

Oct 9, 2025, 4:05 PM EDT - 4 months ago

VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock and Common Stock Warrants

Oct 8, 2025, 4:56 PM EDT - 4 months ago

VolitionRx Limited - Special Call

Oct 2, 2025, 8:45 AM EDT - 5 months ago

Volition Sponsors Upcoming GenomeWeb Webinar

Sep 29, 2025, 9:30 AM EDT - 5 months ago

Volition Signs Co-Marketing and Services Agreement with Hologic

HOLX

Sep 9, 2025, 8:45 AM EDT - 5 months ago

Volition Signs First Human Out Licensing Deal

Aug 15, 2025, 2:24 PM EDT - 6 months ago

VolitionRx Limited (VNRX) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 4:10 PM EDT - 6 months ago

VolitionRx Limited Announces Second Quarter 2025 Financial Results and Business Update

Aug 8, 2025, 8:30 AM EDT - 7 months ago

VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update

Aug 4, 2025, 4:01 PM EDT - 7 months ago

VolitionRx Announces Pricing of $1.2 Million Registered Direct Offering

Jul 16, 2025, 8:00 AM EDT - 7 months ago

Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation

Jul 8, 2025, 8:00 AM EDT - 8 months ago

Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes

Jun 12, 2025, 8:30 AM EDT - 9 months ago

Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure

Jun 4, 2025, 9:00 PM EDT - 9 months ago

Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties

May 19, 2025, 8:30 AM EDT - 9 months ago

VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats

May 16, 2025, 7:19 PM EDT - 10 months ago

VolitionRX Limited (VNRX) Q1 2025 Earnings Call Transcript

May 15, 2025, 5:37 PM EDT - 10 months ago

VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update

May 12, 2025, 8:30 AM EDT - 10 months ago

VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update

May 7, 2025, 8:30 AM EDT - 10 months ago

VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption

Apr 29, 2025, 8:30 AM EDT - 10 months ago

VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets

Apr 1, 2025, 12:31 AM EDT - 11 months ago

VolitionRx Limited (VNRX) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 4:05 PM EDT - 11 months ago

VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update

Mar 28, 2025, 8:00 AM EDT - 11 months ago

Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025

Mar 27, 2025, 8:30 AM EDT - 11 months ago

Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025

Mar 26, 2025, 8:00 AM EDT - 11 months ago

VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering

Mar 25, 2025, 9:30 AM EDT - 11 months ago

VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update

Mar 21, 2025, 8:30 AM EDT - 1 year ago

Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry

Mar 20, 2025, 8:30 AM EDT - 1 year ago

Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer

Mar 17, 2025, 8:30 AM EDT - 1 year ago

Volition Proudly Sponsors the 44th ISICEM Congress

Mar 13, 2025, 8:30 AM EDT - 1 year ago

Volition Signs first ever Nu.Q® Vet Cancer Test Automation Agreement with Fujifilm Vet Systems

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Volition Announces First Patient Enrolled in NTU Hospital's Prospective Validation Study of Nu.Q® Lung Cancer Test

Mar 4, 2025, 8:30 AM EST - 1 year ago

Volition's Nu.Q® Discover Biomarkers to be utilized in Human Clinical Study Sponsored by Leading Pharmaceutical Company for the First Time

jetty323 Feb. 21 at 3:04 AM

1 · Reply

moemog Feb. 20 at 12:50 AM

$VNRX 🚀💣 🔥🌡️⚡☄️🚨🚒🛫✈️

1 · Reply

jetty323 Feb. 20 at 12:35 AM

$VNRX This is great news! I'm sure there will quickly be a follow up into the market with this. Crickets for six weeks now, beautiful execution!! Now that's the leadership this company needs

1 · Reply

jetty323 Feb. 19 at 4:38 AM

1 · Reply

SerendipiTea Feb. 19 at 1:39 AM

1 · Reply

ReturnStacking Feb. 17 at 12:54 PM

$VNRX Pre-revenue biotech; early-stage.

1 · Reply

moemog Feb. 17 at 12:20 PM

$VNRX ☕

0 · Reply

Kululu Feb. 13 at 9:08 PM

$VNRX this crap don’t even act like a Penny stock. Penny stocks sometimes go for 200-400 % run for no reason. It’s just bs stock

0 · Reply

2021er Feb. 12 at 7:13 PM

$VNRX

1 · Reply

jetty323 Feb. 12 at 6:48 AM

0 · Reply

jetty323 Feb. 11 at 11:34 PM

$VNRX teens eow

0 · Reply

moemog Feb. 11 at 6:18 PM

$VNRX Feed me more! Been adding dips .. See you up there 🚀 MoG

2 · Reply

Kululu Feb. 11 at 2:36 PM

$VNRX we will never have a good day like other stocks. It’s just sad

0 · Reply

NetworkNewsWire Feb. 10 at 7:21 PM

InvestorNewsBreaks – $VNRX Appoints MBL as Distributor for Nu.Q(R) Discover Assays in Japan https://ibn.fm/4631o

0 · Reply

Kululu Feb. 10 at 5:03 PM

$VNRX all fluff news. Nothing to do with revenues

0 · Reply

MarshallHiggins Feb. 10 at 12:22 AM

$VNRX bail on this crapola

0 · Reply

JordanBrokePort Feb. 9 at 2:52 PM

$VNRX Biotech with oncology pipeline; clinical data will be a major catalyst.

1 · Reply

Kululu Feb. 6 at 3:46 PM

$VNRX all the stocks are trying to go into positive direction following market. This crap falls everyday irrespective of what market does.

0 · Reply

dndodd Feb. 4 at 11:10 AM

$VNRX you do realize in there latest filings they are essentially going to recapitalize the company and do a RS?

2 · Reply

moemog Feb. 2 at 11:39 PM

$VNRX whose ready? Buckle up. I said BUCKLE UP 🚀 MoG IIIII said

3 · Reply

2021er Feb. 2 at 9:04 PM

$VNRX closed over 0 25✅️

1 · Reply

moemog Jan. 31 at 12:57 PM

$VNRX I was off by couple days when I thought the move would start. The next leg up will be Monday. Buckle up 🚀 MoG

1 · Reply

Market Cap	26.77M
Revenue (ttm)	1.23M
Net Income (ttm)	-26.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,192.68%
Debt to Equity Ratio	-0.22

Volume	1,180,700
Avg Vol	2,268,162
Day's Range	N/A - N/A
Shares Out	135.57M
Stochastic %K	18%
Beta	1.29
Analysts	Strong Sell
Price Target	$2.20